We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00128102
Recruitment Status : Completed
First Posted : August 9, 2005
Last Update Posted : April 20, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.